Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PLSE
stocks logo

PLSE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast PLSE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLSE is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast PLSE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLSE is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.270
sliders
Low
22.00
Averages
22.00
High
22.00
Current: 13.270
sliders
Low
22.00
Averages
22.00
High
22.00
Oppenheimer
Suraj Kalia
Outperform
initiated
$22
2025-07-07
Reason
Oppenheimer
Suraj Kalia
Price Target
$22
2025-07-07
initiated
Outperform
Reason
Oppenheimer analyst Suraj Kalia initiated coverage of Pulse Biosciences with an Outperform rating and $22 price target. The company has developed nanosecond pulsed field ablation technology and preliminary evidence suggests a better safety and efficacy profile versus traditional treatments in key applications like thyroid ablation, the analyst tells investors in a research note. The firm says Pulse has multiple shots on goal and an experienced CEO.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pulse Biosciences Inc (PLSE.O) is -8.56, compared to its 5-year average forward P/E of -9.78. For a more detailed relative valuation and DCF analysis to assess Pulse Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.78
Current PE
-8.56
Overvalued PE
-2.92
Undervalued PE
-16.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
104.69
Current PS
0.00
Overvalued PS
305.95
Undervalued PS
-96.56
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PLSE News & Events

Events Timeline

(ET)
2025-10-24
07:30:13
Pulse Biosciences initiates NANOCLAMP AF study with first patient enrollment
select
2025-09-08 (ET)
2025-09-08
07:04:53
Pulse Biosciences Receives FDA Approval for Investigational Device Exemption
select
2025-09-02 (ET)
2025-09-02
07:03:15
Pulse Biosciences initiates first procedures in study on benign thyroid nodules
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-13NASDAQ.COM
Pulse Biosciences (PLSE) is Currently Oversold

  • Pulse Biosciences Stock Performance: Pulse Biosciences Inc (PLSE) shares have entered oversold territory with an RSI of 29.3, indicating potential exhaustion of recent selling pressure as the stock trades around $14.93.

  • Comparison with S&P 500: The current RSI of the S&P 500 ETF (SPY) is 56.4, suggesting that PLSE's lower RSI may present a buying opportunity for bullish investors.

  • 52-Week Range: PLSE's 52-week low is $13.7658 and the high is $25, with the last trade recorded at $14.97.

  • Author's Views: The opinions expressed in the article are those of the author and do not necessarily reflect the views of Nasdaq, Inc.

[object Object]
Preview
3.0
10-24NASDAQ.COM
Our Calculations Show ISCG Could Reach $64

  • ETF Analysis: The iShares Morningstar Small-Cap Growth ETF (ISCG) has an implied analyst target price of $64.03, indicating a potential upside of 15.53% from its current trading price of $55.42.

  • Notable Holdings: Key underlying holdings with significant upside potential include Zymeworks Inc (ZYME), Winmark Corp (WINA), and Pulse Biosciences Inc (PLSE), with expected price increases of 36.02%, 27.21%, and 26.47% respectively.

  • Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets may lead to downgrades if they are based on outdated information.

  • Investor Research: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent company and industry developments.

[object Object]
Preview
5.0
10-16Newsfilter
Pulse Biosciences Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)

  • Equity Awards Granted: Pulse Biosciences has granted equity inducement awards to three new employees, allowing them to purchase a total of 8,550 shares of common stock at an exercise price of $17.26 per share, in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Vesting Terms: The stock options are subject to time-based vesting over four years, with 1/4 of each award vesting annually, contingent on the employees' continued employment with the company.

  • Company Overview: Pulse Biosciences is focused on health innovation through its proprietary nPulse™ technology, which utilizes nanosecond pulsed field ablation to treat conditions like atrial fibrillation and perform surgical soft tissue ablation.

  • Trademarks: The company holds several trademarks related to its technology and products, including nPulse, CellFX, and Nano-Pulse Stimulation, in the United States and other countries.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pulse Biosciences Inc (PLSE) stock price today?

The current price of PLSE is 13.27 USD — it has decreased -1.63 % in the last trading day.

arrow icon

What is Pulse Biosciences Inc (PLSE)'s business?

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.

arrow icon

What is the price predicton of PLSE Stock?

Wall Street analysts forecast PLSE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLSE is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pulse Biosciences Inc (PLSE)'s revenue for the last quarter?

Pulse Biosciences Inc revenue for the last quarter amounts to 86.00K USD, decreased % YoY.

arrow icon

What is Pulse Biosciences Inc (PLSE)'s earnings per share (EPS) for the last quarter?

Pulse Biosciences Inc. EPS for the last quarter amounts to -0.29 USD, increased 38.10 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pulse Biosciences Inc (PLSE)'s fundamentals?

The market is revising No Change the revenue expectations for Pulse Biosciences, Inc. (PLSE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -12.18%.
arrow icon

How many employees does Pulse Biosciences Inc (PLSE). have?

Pulse Biosciences Inc (PLSE) has 75 emplpoyees as of December 05 2025.

arrow icon

What is Pulse Biosciences Inc (PLSE) market cap?

Today PLSE has the market capitalization of 899.28M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free